TQB2868
TQB2868 is a bispecific antibody from Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., in registered phase 2 trials for pancreatic ductal adenocarcinoma.
Overview
TQB2868 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., in pancreatic ductal adenocarcinoma. A bispecific antibody, as described in the registry record: one molecule binds two different targets, most often a tumour antigen and an immune cell or a second tumour pathway. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
A bispecific antibody, as described in the registry record: one molecule binds two different targets, most often a tumour antigen and an immune cell or a second tumour pathway.
1.One arm of TQB2868 binds its target on the cancer cell.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"TQB2868" OR ABSTRACT:"TQB2868") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TQB2868, not a curated reading list.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Pancreatic ductal adenocarcinoma and the tag pipeline.
- TreatmentTQB3909
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tags pipeline, registry-only.
- TreatmentTQB3702
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tags pipeline, registry-only.
- TreatmentPBP1510
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
- TreatmentCT3001
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
- TreatmentMitazalimab
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
- TreatmentLP-184
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
- TreatmentPonsegromab
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.